Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial

CHIH-CHIEH YULai, Wen-TerWen-TerLaiShih, Kuang-ChungKuang-ChungShihLin, Tsung-HsienTsung-HsienLinLu, Chieh-HuaChieh-HuaLuLai, Hung-JenHung-JenLaiHanson, Mary EMary EHansonHWANG, JUEY-JENJUEY-JENHWANG2022-09-192022-09-192012-05-231756-0500https://scholars.lib.ntu.edu.tw/handle/123456789/621146Reducing low-density lipoprotein cholesterol (LDL-C) is associated with reduced risk for major coronary events. Despite statin efficacy, a considerable proportion of statin-treated hypercholesterolemic patients fail to reach therapeutic LDL-C targets as defined by guidelines. This study compared the efficacy of ezetimibe added to ongoing statins with doubling the dose of ongoing statin in a population of Taiwanese patients with hypercholesterolemia.enAtorvastatin | Ezetimibe | Pravastatin | Simvastatin[SDGs]SDG3Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialjournal article10.1186/1756-0500-5-251226213162-s2.0-84861333456https://scholars.lib.ntu.edu.tw/handle/123456789/534622